Leishmaniasis
Studies from Federal University have provided new data on leishmaniasis
Published in TB and Outbreaks Week, May 26th, 2009
"Despite clinical importance of leishmaniasis, an infectious disease that affects 12 thousand million people in 88 countries, the treatment is still unsatisfactory due to its limited efficacy, cost expensive and undesirable side effects. Aiming to develop new antileishmanial lead compounds, we used a rational approach to synthesize a new set of sulfonamide 4-methoxychalcone derivatives (3a-3i) and evaluate the sulfonamide and methoxy moieties as promising adding-groups to chalcones," scientists in Niteroi, Brazil report.
"For that purpose we tested this new set against Leishmania braziliensis promastigotes and intracellular amastigotes and determined its cell toxicity...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- BioMed Central
Would NHS staff go to work during a flu pandemic? - Imperial College London
Swine flu: Early findings about pandemic potential reported in new study - Emergent BioSolutions Inc.
Emergent BioSolutions Launches BioThrax.com, an Educational Website about BioThrax Anthrax Vaccine Adsorbed and Anthrax Disease - Pediatrics
Does Mom Know When Enough Is Enough? Missed satiety cues from infants linked to obesity - ReportLinker
High Growth Forecasted for the Swine Influenza Market Alert Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays - Smallpox
Scientists discover how smallpox may derail human immune system - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
